Glint Pharmaceuticals

Glint Pharmaceuticals is a small company based in the United States, with a team of three employees. While revenue is currently under $10,000, the company is rapidly developing and commercializing a groundbreaking technology. Glint Pharmaceuticals focuses on the development and commercialization of a patented nano barrier technology designed for the treatment of various eye diseases. This innovative technology integrates a drug delivery mechanism into a single-use, disposable contact lens, offering a non-surgical approach to eye care. Their patented Glint lens has the potential to treat a wide range of conditions, including glaucoma, ocular surgery complications, eye trauma, and corneal surface abnormalities. The company's technology addresses a significant unmet need in eye care. Corneal injuries, which can result from trauma, infection, or surgery, affect millions of people annually in the United States and Europe, with a substantial risk of blindness. Conventional eye drop therapy often suffers from low patient compliance due to the high frequency of administration. Glint Pharmaceuticals aims to improve patient compliance and treatment outcomes by providing a convenient, cost-effective, and more effective alternative to traditional eye drop therapy. For more information about Glint Pharmaceuticals and their innovative technology, please visit their website at glintpharma.com.